Transverse Tibial Bone Transfer in the Treatment of Diabetes Foot Ulcer: A Pilot Study
Rongzhi Wen,Xinhua Cheng,Hong Cao,Lei Zhang,Fangcheng Luo,Wei Shang
DOI: https://doi.org/10.2147/DMSO.S413884
2023-07-03
Abstract:Rongzhi Wen, &ast Xinhua Cheng, &ast Hong Cao, Lei Zhang, Fangcheng Luo, Wei Shang Department of Orthopaedics, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Fangcheng Luo; Wei Shang, Email ; Background: The treatment of diabetes-related foot complications is a clinical challenge. The underlying complicating factors of peripheral vascular disease render most diabetic foot ulcers asymptomatic until the ulcer fails to heal and becomes clinically distinct, constituting a significant cause of disability and even death in diabetic patients. Objective: To evaluate the clinical efficacy of tibial transverse transport (TTT) in the treatment of patients with diabetic foot ulcers. Methods: A total of 35 patients who met the inclusion criteria were selected as the study group from patients with diabetic foot ulcers diagnosed and treated at our hospital between August 2019 and March 2021 and were treated with TTT, and 35 patients who also met the inclusion criteria were included in the routine group and were given conventional wound debridement. The primary endpoint of this study was clinical efficacy, including pain condition, trauma condition, ankle-brachial index, and peripheral nerve recovery. Results: Patients receiving TTT showed significantly reduced visual analogue scale (VAS) scores than those with conventional treatment (P< 0.05). TTT resulted in a significant reduction of trabecular area and better trabecular healing versus conventional treatment (P< 0.05). TTT was associated with significantly higher ankle-brachial index (ABI) and lower Michigan neuropathy screening instrument (MNSI) scores in patients versus conventional debridement (P< 0.05). Conclusion: TTT effectively alleviates the pain of diabetic foot ulcer patients, promotes wound healing, and improves ankle-brachial index and peripheral nerve recovery. In the context of the high amputation rate of diabetic foot ulcers treated by internal medicine, TTT contributes positively to the enhancement of patient prognosis and merits clinical promotion. Keywords: tibial transverse transport, diabetic foot ulcer, clinical efficacy Diabetes is associated with a range of microvascular and macrovascular changes and their associated widespread complications. 1 There are over 400 million patients with diabetes, with a prevalence of diabetic foot ulcers (DFU) being 12–15% among all diabetic cases. Common risk factors for the development of foot ulcers include poor glycemic control, peripheral neuropathy, peripheral vascular disease, and immunosuppression. 2,3 Boulton reported that up to 85% of diabetic foot ulcers were attributable to altered foot pressure due to underlying peripheral neuropathy. According to relevant epidemiological statistics, approximately 50%-70% of lower extremity amputations are induced by diabetes mellitus. Diabetic foot ulcers are complex chronic traumas that significantly influence the morbidity, mortality, and quality of life of patients. In recent years, the incidence of diabetic foot in China has been increasing year by year. With a prevalence rate of 8.1%, amputation rate of 22% and mortality rate of 11% among people over 50 years old, diabetic foot has constituted a serious public issue in China. The outcome of traditional bypass surgery and interventional treatment is undesirable, as evidenced by the high incidence of postoperative restenosis or occlusion. Peripheral vascular and neurological lesions in patients with diabetic foot ulcers severely delay wound healing and even cause amputation due to difficult repair. Therefore, effective reconstruction of the local blood supply and reduction of amputation rate are the keys to the management of diabetic foot ulcers. At present, the major treatment for diabetic foot includes blood glucose control, 4 surgical treatment mainly includes debridement, vascular intervention and arterial bypass graft, 5 etc. Various topical products such as PDGF preparation, stem cell preparation, 6 LeucoPatch patch, 7 sucrose octasulphate dressing 8 and related adjuvant treatments (eg nitric oxide generation device, 9 hyperbaric oxygen, 10 etc.) have yielded favorable outcomes, they however did not fundamentally change the pathological state of diabetic foot with ischemia and hypoxia, and a large number of patients with refractory diabetic foot have their limbs amputated eventually. Tibial transverse transport was proposed by Ilizarov, which was initially used to correct limb deformities and achieved promising results. 11,12 It has been ext -Abstract Truncated-
endocrinology & metabolism